Editas Medicine, Inc. (EDIT): Capital Expenditures
$607.0K
Year ended 2025-12-31
$691.0K
Trailing 12 months to 2026-06-30
-47.2%
3-year compound annual growth
-39.0%
5-year compound annual growth
-8.2%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $607.0K | -93.1% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $8.83M | +87.0% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $4.72M | +14.6% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $4.12M | -48.4% | 2025-03-05, From 2022-01-01 |
| 2021-12-31 | $7.98M | +11.4% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $7.16M | +16.1% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $6.17M | +29.7% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $4.75M | +130.9% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $2.06M | -41.1% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $3.49M | +144.1% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $1.43M | +17.6% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $1.22M | n/a | 2017-03-03, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗